It represents a kind of adaptation of the cell to its environment. As described in a paper released on, may 9 in the Proceedings of the National Academy of Sciences USA, the laboratories of Prof Hayes, Dr Dr and McLellan Lindsay possess designed a nucleic acid molecule, of the sort siRNA called, which interferes with the expression of Keap1. When presented into individual skin cells, they found that the siRNA against Keap1 caused levels of Keap1 to be depleted, leading to accumulation of activation and Nrf2 of antioxidant genes.Because the clinical program were only available in 2013, two Phase I trials have been completed in healthful volunteers and obese/obese subjects. The full total results indicate that AZP-531 was well tolerated, with improved glucose control and decreased weight in obese topics over a two-week treatment period. The program is in Phase II clinical development for the treating Prader-Willi syndrome and in Phase Ib for type 2 diabetes.
AGA acknowledges partnership of GCF to support study in gastric, esophageal cancer The American Gastroenterological Association Research Base is very happy to announce that it has partnered with the Gastric Cancer Base to make a new grant to support research in gastric and esophageal cancer.